Literature DB >> 16739767

New drugs: lubiprostone, ranolazine, and anidulafungin.

Daniel A Hussar1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16739767     DOI： 10.1331/154434506777069453

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN： 1086-5802


× No keyword cloud information.
  3 in total

1.  Lubiprostone decreases the small bowel transit time by capsule endoscopy: an exploratory, randomised, double-blind, placebo-controlled 3-way crossover study.

Authors:  Mizue Matsuura; Masahiko Inamori; Hiroki Endo; Tetsuya Matsuura; Kenji Kanoshima; Yumi Inoh; Yuji Fujita; Shotaro Umezawa; Akiko Fuyuki; Shiori Uchiyama; Takuma Higurashi; Hidenori Ohkubo; Eiji Sakai; Hiroshi Iida; Takashi Nonaka; Seiji Futagami; Akihiko Kusakabe; Shin Maeda; Atsushi Nakajima
Journal:  Gastroenterol Res Pract       Date:  2014-12-29       Impact factor: 2.260

2.  Lubiprostone improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled 2-way crossover study.

Authors:  Mizue Matsuura; Masahiko Inamori; Yumi Inou; Kenji Kanoshima; Takuma Higurashi; Hidenori Ohkubo; Hiroshi Iida; Hiroki Endo; Takashi Nonaka; Akihiko Kusakabe; Shin Maeda; Atsushi Nakajima
Journal:  Endosc Int Open       Date:  2017-05-31

3.  Lubiprostone Increases Small Intestinal Smooth Muscle Contractions Through a Prostaglandin E Receptor 1 (EP1)-mediated Pathway.

Authors:  Walter W Chan; Hiroshi Mashimo
Journal:  J Neurogastroenterol Motil       Date:  2013-07-08       Impact factor: 4.924
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.